Wechselwirkungen von Paclitaxel

Use of REYATAZ without ritonavir is not recommended when coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide). (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

Pneumonitis Pneumonitis, including some cases that were fatal, occurred in 4% of patients receiving protein bound paclitaxel in combination with gemcitabine. (Fachinformation zu Paclitaxel, Warnhinweise und Vorsichtsmaßnahmen)

…within at least 72 hours of treatment with ketoconazole Antineoplastics irinotecan dasatinib, lapatinib, nilotinib bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, paclitaxel, trimetrexate, vinca alkaloids Irinotecan: The potential increase in plasma concentrations of irinotecan when coadministered with ketoconazole tablets may increase the risk… (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

• NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (Fachinformation zu Sorafenib, Gegenanzeigen)

AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (Fachinformation zu Trastuzumab, Warnhinweise und Vorsichtsmaßnahmen)

…patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly protein-bound paclitaxel for Injectable Suspension (albumin-bound) and every-3-week carboplatin after ANC recovers to at least 1,500 cells/mm 3 and platelet count of at least 100,000 cells/mm 3 on Day 1 or to an ANC of at least 500 cells/mm 3 and platelet count of… (Fachinformation zu Paclitaxel, Warnhinweise und Vorsichtsmaßnahmen)

…that Potentiate Cyclophosphamide Toxicities Toxicity Drugs Increased hematotoxicity and/or immunosuppression ● ACE inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ●… (Fachinformation zu Cyclophosphamid, Arzneimittelwechselwirkungen)

Agents Metabolized by CYP2C8 Deferasirox inhibits CYP2C8 resulting in an increase in CYP2C8 substrate (e.g., repaglinide and paclitaxel) concentration when these drugs are coadministered. (Fachinformation zu Deferasirox, Arzneimittelwechselwirkungen)

Paclitaxel Paclitaxel, when given prior to doxorubicin hydrochloride, increases the plasma-concentrations of doxorubicin and its metabolites. (Fachinformation zu Doxorubicin, Arzneimittelwechselwirkungen)

Table 7: Drugs Affected by Phenytoin Interacting Agent Examples Drugs whose efficacy is impaired by phenytoin Azoles Fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole Antineoplastic agents Irinotecan, paclitaxel, teniposide Delavirdine Phenytoin can substantially reduce the concentrations of delavirdine. (Fachinformation zu Fosphenytoin, Arzneimittelwechselwirkungen)

(C) CYP2C8 Substrates Gemfibrozil is a strong inhibitor of CYP2C8 and may increase exposure of drugs mainly metabolized by CYP2C8 (e.g., dabrafenib, enzalutamide, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone). (Fachinformation zu Gemfibrozil, Arzneimittelwechselwirkungen)

Paclitaxel : In cancer patients receiving TYKERB and paclitaxel (CYP2C8 and P-gp substrate), 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. (Fachinformation zu Lapatinib, Arzneimittelwechselwirkungen)

In patients taking ARAVA, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. (Fachinformation zu Leflunomid, Arzneimittelwechselwirkungen)

Table 3: Drugs Affected by Phenytoin Interacting Agent Examples Drugs whose efficacy is impaired by phenytoin Azoles Fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole Antineoplastic agents Irinotecan, paclitaxel, teniposide Delavirdine Phenytoin can substantially reduce the concentrations of delavirdine. (Fachinformation zu Phenytoin, Arzneimittelwechselwirkungen)

In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. (Fachinformation zu Teriflunomid, Arzneimittelwechselwirkungen)

Concomitant administration of R verapamil can decrease the clearance of paclitaxel. (Fachinformation zu Verapamil, Arzneimittelwechselwirkungen)

Etoposide, vinorelbine, paclitaxel, and docetaxel No dosage adjustment needed. (Fachinformation zu Aprepitant, Arzneimittelwechselwirkungen)

Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (Fachinformation zu Bevacizumab, Arzneimittelwechselwirkungen)

Etoposide, vinorelbine, paclitaxel, and docetaxel No dosage adjustment needed. (Fachinformation zu Fosaprepitant, Arzneimittelwechselwirkungen)